Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients - Wikidata - wikimedia - TriplyDB

Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients

Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients

http://www.wikidata.org/entity/Q28740575

about

RANK-RANKL signalling in cancer Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?Targeting RANKL in metastasis Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences Cancer Cell Colonisation in the Bone Microenvironment Osteoprotegerin in breast cancer: beyond bone remodeling Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro Effects of TLR-2/NF-κB signaling pathway on the occurrence of degenerative knee osteoarthritis: an in vivo and in vitro study.Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.Pathophysiology of Bone Remodelling and Current Therapeutic Approaches.Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.Mammary carcinoma with osteoclast-like giant cells: a case report.Evaluation of rs3102735 and rs2073617 Osteoprotegerin Gene Polymorphisms and the Risk of Childhood Acute lymphoblastic Leukemia in Zahedan Southeast Iran.RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities.Chronic stress, sympathetic activation and skeletal metastasis of breast cancer cells.Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives C-Src-mediated RANKL-induced breast cancer cell migration by activation of the ERK and Akt pathway.RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1.Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines.The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis.RANK/RANKL pathway in cancer: Biological activity beyond bone?The deep-sea natural products, biogenic polyphosphate (Bio-PolyP) and biogenic silica (Bio-Silica), as biomimetic scaffolds for bone tissue engineering: fabrication of a morphogenetically-active polymer.Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis.A new emergency in oncology: Bone metastases in breast cancer patients (Review)Role of RANKL/RANK in primary and secondary breast cancer.Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.Effects of RANKL-Targeted Therapy in Immunity and Cancer.The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases.The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.Premetastatic niche: ready for new therapeutic interventions?Skeletal and extraskeletal actions of denosumab.Role of nuclear factor-ĸB in breast and colorectal cancer.Targeting RANKL in breast cancer: bone metastasis and beyond.Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis.Novel NF-κB inhibitors: a patent review (2011 - 2014).Emerging drugs for the treatment of bone metastasis.

P2860

Q26747442-C5ABE36F-6993-41FD-9B66-0759CA441337 Q26849473-3BEC0498-9829-4565-B40A-50A717DA79AC Q26849690-51E9DC4D-721A-438C-9143-4BB34EE1729A Q26863493-A4550354-1CA1-4F92-9B29-AB3B35E845A7 Q28072561-5A71432B-FA33-4FB2-BF70-66E698FDB100 Q28081803-D4826D4A-866B-4D25-8AA9-04B29314F0F3 Q28087676-16C5E8C8-85D0-45B3-9B02-02B3A33C3E47 Q30419245-3FD66AD4-AC5B-44B7-96F6-7673DF739210 Q33888890-4B6E275F-65EE-450D-94F2-4A04D6FCAC1C Q34101059-6E794C89-57DD-4D5D-9F08-35327D95935F Q34209272-15C75A4D-223D-4004-B678-C6D0F284DB51 Q34209614-C655CBC0-2390-4865-9506-3BD259559353 Q34629549-6A3AE314-4B1B-40CE-8553-2F5D9D9634C8 Q35038508-558DD556-3D3B-48FC-AE31-47E064EAA448 Q35133898-50531BF4-E20B-4B9C-9C5C-E4502472039F Q35405350-A046B1E8-461F-4FBE-914F-DB2E8321AC53 Q35609448-36836343-9FCF-4D61-8494-3C153B0A9706 Q35667318-8889635C-7015-4FF3-A7F5-C2C86BF9153A Q35995710-C8BC7370-01CD-4FBF-81ED-28F341FB2727 Q36200979-4AEE5804-D5B9-4D3D-BDCE-14E509F8C379 Q36252676-FAE7E02D-DBCD-4154-8E6F-DFE01208173A Q36273402-7567F0EF-ECCE-499D-A88C-3452327EDD5B Q36338510-2038FBFA-FC1D-4D8E-B21A-0F77D3BCF818 Q36356112-B0BAF477-F027-40DB-A09C-21B118F26055 Q36491425-6A79223E-55F6-46B5-BACC-FB29BC41463E Q36994140-A6E771CA-B699-45EC-A207-E83118A9011C Q37056973-66CF4E01-C1F0-4147-930D-73F7DDCB584B Q37211824-236F6642-B6DE-45F9-A1A3-EDC89ED37694 Q37241255-982C202B-17D7-42DA-967B-A68A630ECDD7 Q37356654-373A99F7-26E9-4791-9AC5-ADAA2D6E7EF6 Q37441693-B1859746-3A19-4E36-8353-1A4F2F81D5CF Q37520235-F69CABFF-B3CE-491E-AFE2-C6B92DDB7AEF Q37615017-C4CB25CC-4746-4F6F-9030-D018C485B770 Q37996455-B2D7E6AC-C8D8-4160-BC28-125573439B0D Q38009712-FB3CA6E7-31DE-4BB5-96B0-086A14058EA4 Q38041500-A288CE99-2144-423E-A096-76548EA04E59 Q38081245-A5D5CE4B-A0E3-4E91-B716-3DA01D914EAB Q38155200-5D1A6673-1143-41BE-BF12-A8379F6F2455 Q38305549-B291CEAA-5EB5-4229-8D63-D25951FA6388 Q38538263-C6640DB5-63CB-4334-877B-7B3A3245EB74

P2860

Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients

http://www.wikidata.org/entity/Q28740575

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@ast

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@en

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@nl

type

label

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@ast

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@en

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@nl

prefLabel

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@ast

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@en

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@nl

P1433

Q28740575-01726EE0-C8ED-4CA2-A394-40A783C4D025

P1476

Q28740575-FE5D570D-75D3-40C0-9C22-67A23110367D

P2093

Q28740575-002C720D-D9AF-42FB-BC83-386320A62EA7

Q28740575-295888C1-3CDD-4D60-849A-B350E0A920A5

Q28740575-3775455A-00B7-408F-AE68-3B9F3982AF1A

Q28740575-39ECA151-0E2D-4FA2-8DE5-112E656D6A9B

Q28740575-4429C084-E5AE-4676-AEAB-05F543F748A9

Q28740575-482FA6EE-3D01-4071-A1B3-21E9B203698D

Q28740575-4F4B4B01-D0B7-4571-B20D-909F5E282543

Q28740575-7FB20CBB-11F5-4983-971C-58A7F9A34A0A

Q28740575-C168C905-DAD8-4460-8438-DF58F60E9F19

Q28740575-D3F1ADCE-B849-4188-85B7-D897612C0BC4

P2860

Q28740575-00B0358F-F999-428E-8D72-3E010419F8D2

Q28740575-0233E4FD-CE60-4128-8C7E-3A64FF55B71B

Q28740575-09B821E1-3ED7-4D51-BEB9-3B07F94B9497

Q28740575-1254E9D6-DCE5-4DFA-B84C-6662BDBDC73D

Q28740575-1CD01B6F-7AC5-44EC-B4D8-ABFAE1BD7962

Q28740575-251202A8-4849-4F1A-8DDC-1F910DFC61F2

Q28740575-33F29951-C22C-4DAA-9D4D-7C4FC52BFAF1

Q28740575-36987FC2-4DDC-439C-97A2-629D72888BA0

Q28740575-37B79A2D-B14C-40F2-9923-9EE402859D43

Q28740575-45BE8EFA-D138-44BC-BEF0-AB4489AF8C41

P304

Q28740575-F4A02604-E31F-41FD-8A80-CDD85982E50C

P31

Q28740575-7B3C2657-B19E-4CBB-8907-5B3E775231BE

P3181

Q28740575-9FE1FF79-DF5C-489D-B599-D80E9D8F8F82

P356

Q28740575-3CE279BC-A2F1-461A-BA01-606225A2EF13

P407

Q28740575-157A6E7B-B42F-4E95-923D-47D724A3BD7C

P433

Q28740575-4B690419-7A3B-4466-8B17-9841ABD8E164

P478

Q28740575-6980DDE2-CC39-4C2E-A3FD-13D4196091DB

P50

Q28740575-0982F4AF-5BC5-41C1-9688-4DF3F11B84FE

Q28740575-2A30C413-F460-4FD8-A6DB-98311EDA99B3

Q28740575-62E27818-96F0-45BA-91E6-A9C2C3C17869

Q28740575-8F80DFE6-2FC0-4753-BFC5-725F6BBFA394

Q28740575-93B9E318-C1D0-483F-A186-B579B38FDB75

Q28740575-E79B3F8A-8099-451B-9839-A34C0369C650

Q28740575-EB4A22F3-1F38-4D7C-A567-5C58AC5A919E

Q28740575-FF5E8774-6E13-4FC0-ACE0-8C994A1177AD

P577

Q28740575-CA514E50-9304-4A3B-B507-C64FDD5CBEA7

P5875

Q28740575-917E406C-A4C6-4BA8-A798-CF256F241C57

P698

Q28740575-E2EE8D7F-966E-4C25-88F2-48DE3C830574

P932

Q28740575-1A4A97E5-A1E1-47DA-8517-C19F1B68A51B

P3181

P356

JOURNAL.PONE.0019234

P1433

P1476

Receptor activator of NF-kB (R ...... ence in breast cancer patients

@en

P2093

Alessandro Ruggiero

http://www.w3.org/2001/XMLSchema#string

Antonio Russo

http://www.w3.org/2001/XMLSchema#string

Cinzia Caroti

http://www.w3.org/2001/XMLSchema#string

Cinzia Ortega

http://www.w3.org/2001/XMLSchema#string

Gaia Schiavon

http://www.w3.org/2001/XMLSchema#string

Grazia Armento

http://www.w3.org/2001/XMLSchema#string

Isabelle Treilleux

http://www.w3.org/2001/XMLSchema#string

Laura Gaeta

http://www.w3.org/2001/XMLSchema#string

Nicla La Verde

http://www.w3.org/2001/XMLSchema#string

Philippe Clezardin

http://www.w3.org/2001/XMLSchema#string

P2860

RANK is essential for osteoclast and lymph node development

Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation

Nonparametric Estimation from Incomplete Observations

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

A gene-expression signature as a predictor of survival in breast cancer

Denosumab in postmenopausal women with low bone mineral density

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

A multigenic program mediating breast cancer metastasis to bone

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

P304

e19234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1332924

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0019234

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Santini

Giuseppe Tonini

Francesco Pantano

Andrea Onetti Muda

Giuseppe Perrone

P577

2011-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51114508

http://www.w3.org/2001/XMLSchema#string

P698

21559440

http://www.w3.org/2001/XMLSchema#string

P932

3084800

http://www.w3.org/2001/XMLSchema#string